Compositions and methods for the prevention and treatment of cardiovascular diseases

A therapeutic composition consisting of the product of a method of preparing a therapeutic composition with a stable negative oxidation-reduction potential in a range between −50 mV and −900 mV, a conductivity between 11 and 15 mS/cm and a pH in the range between 6.5 and 7.6, the method comprising:

• mixing a first electroactivated solution with a second electroactivated solution, the first electroactivated solution having a stable negative oxidation-reduction potential and the second electroactivated solution having a stable positive oxication oxidation-reduction potential, wherein
• the first electroactivated solution has an oxidation-reduction potential in the range between −500 mV and −900 mV for a period of at least 12 months and a pH in the range between 3.2 and 4.5, and one liter of the first electroactivated solution consists of:
• 83.6-95.5 g/L ascorbic acid;
• 57.1-64.7 g/L magnesium sulfate hexahydrate;
• 9.4-10.6 g/L niacinamide;
• 9.4-10.6 g/L pyridoxin HCl;
• 0.18-0.29 g/L riboflavin-5-phosphate sodium;
• 5.75-6.5 g/L thiamin HCl;
• 0.17-0.2 g/L cyanocobalamin crystalline;
• and electrochemically activated water,
• the second electroactivated solution has an oxidation-reduction potential in the range between +500 mV and +900 mV for a period of at least 12 months and a pH in the range between 6.5 and 7.8, and one liter of the second electroactivated solution consists of:
• 82.4-93.2 g/L sodium bicarbonate USP, 19.1-21.8 g/L magnesium sulfate hexahydrate;
• and electrochemically activated water,
• and the step of mixing comprises mixing equal volumes of the first electroactivated solution and the second electroactivated solution.